CRS, ICANS, and management
| CRS . | . |
|---|---|
| Any grade, n (%) | 15 (75%) |
| Grade 1 | 7 (35%) |
| Grade 2 | 4 (20%) |
| Grade 3 | 4 (20%) |
| Grade 4 | 0 (0%) |
| Median time to onset, d (range) | 3 (1-12) |
| Median duration of CRS, d (range) | 4 (1-15) |
| Tocilizumab use, n (%) | 8 (40%) |
| Vasopressor use, n (%) | 2 (10%) |
| CRS . | . |
|---|---|
| Any grade, n (%) | 15 (75%) |
| Grade 1 | 7 (35%) |
| Grade 2 | 4 (20%) |
| Grade 3 | 4 (20%) |
| Grade 4 | 0 (0%) |
| Median time to onset, d (range) | 3 (1-12) |
| Median duration of CRS, d (range) | 4 (1-15) |
| Tocilizumab use, n (%) | 8 (40%) |
| Vasopressor use, n (%) | 2 (10%) |
| Neurotoxicity (ICANS) . | . |
|---|---|
| Any grade, n (%) | 2 (10%) |
| Grade 1 | 1 (5%) |
| Grade 2 | 1 (5%) |
| Corticosteroid dose, median cumulative dexamethasone equivalent (range) | 25 mg (20-30) |
| Duration of neurotoxicity, median days (range) | 3 (2-4) |
| Resolution to grade 0 | 2 (100%) |
| Neurotoxicity (ICANS) . | . |
|---|---|
| Any grade, n (%) | 2 (10%) |
| Grade 1 | 1 (5%) |
| Grade 2 | 1 (5%) |
| Corticosteroid dose, median cumulative dexamethasone equivalent (range) | 25 mg (20-30) |
| Duration of neurotoxicity, median days (range) | 3 (2-4) |
| Resolution to grade 0 | 2 (100%) |
ICANS, immune effector cell–associated neurotoxicity syndrome.